**XGEVA® (denosumab)**

**LENGTH OF AUTHORIZATION:** Up to six months

**REVIEW CRITERIA:**
- Patient must be ≥ 18 years old.
- CONFIRMATION OF ONE OF THE FOLLOWING DIAGNOSES:
  - Bone metastases from solid tumors confirmed by progress notes or medical records.
  - Giant Cell Tumor of the bone that is unresectable or resection will likely cause severe morbidity.
  - Hypercalcemia of malignancy refractory to bisphosphonate therapy.

**DOSING & ADMINISTRATION:**

**Bone metastases from solid tumors:** 120 mg every 4 weeks as a subcutaneous injection in the upper arm, upper thigh, or abdomen.

**Giant Cell Tumor of Bone and Hypercalcemia of Malignancy:** 120 mg given subcutaneously in the upper arm, upper thigh or abdomen on days 1, 8 and 15 initially, then 120 mg subcutaneous every 4 weeks beginning on day 29.